Bicycle Therapeutics plc (BCYC) Social Stream
BICYCLE THERAPEUTICS plc (BCYC) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering BICYCLE THERAPEUTICS plc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 18 months, BCYC's average price target has gone up $45.64.
Over the past 121 days, BCYC's average upside potential has been 41.63%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
BCYC Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
BCYC's average broker recommendation rating worsened by 0.25 over the prior 120 days.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, BICYCLE THERAPEUTICS plc's variance in analysts' estimates is lower than -593.13% of them.
- BICYCLE THERAPEUTICS plc's number of analysts covering the stock is greater than 792.5% of stocks in the small market cap category.
- In terms of how BICYCLE THERAPEUTICS plc fares relative to stocks in the small market cap category, note that its average analyst price target is higher than 762.98% of that group.
- In the context of Pharmaceutical Products stocks, BICYCLE THERAPEUTICS plc's upside potential (average analyst target price relative to current price) is greater than 199.64% of them.
In the Pharmaceutical Products industry, BCEL, AVTE, and AVEO are the three stocks most similar to BICYCLE THERAPEUTICS plc regarding the price target and analyst recommendation information presented here.
Is BCYC a Buy, Hold or Sell? See the POWR Ratings now!